# IQVIA (IQV) Q2 2026 earnings

Results filed 2026-07-28 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/iqv/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1478242/000162828026049923/0001628280-26-049923-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

IQVIA reported record R&D Solutions net new bookings of over $3.1 billion and rising adoption of its AI solutions, and said forward indicators point to sustained momentum into 2027.

IQVIA's R&D Solutions unit, which runs clinical trials for drug developers, signed record net new bookings of over $3.1 billion, lifting contracted backlog to $34.2 billion. In Commercial Solutions, patient solutions and commercial engagement services grew at double-digit rates, and analytics and consulting grew at a high-single-digit organic rate. Management also pointed to increased adoption of its AI solutions. Since January 1, 2026, results have been reported under a simplified two-segment structure.
Management says forward-looking indicators across both segments point to sustained momentum for the rest of 2026 and into 2027, and it raised its full-year outlook. About $9.2 billion of backlog is expected to convert to revenue over the next twelve months. The main tension is execution: the plan relies on turning record bookings into revenue and on the new organizational model delivering its expected benefits, with acquisitions contributing more to growth than previously assumed.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue | $4,368 million | up 8.7% year-over-year | GAAP |
| Net income | $256 million |  | GAAP |
| Diluted EPS | $1.53 |  | GAAP |
| Adjusted diluted EPS | $3.15 | up 12.1% year-over-year | non-GAAP |
| Adjusted EBITDA | $994 million | up 9.2% year-over-year | non-GAAP |
| Operating cash flow | $558 million | up 26.0% year-over-year | GAAP |
| Free cash flow | $360 million | up 23.3% year-over-year | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Commercial Solutions revenue | $1,793 million | up 8.6% year-over-year |
| R&D Solutions revenue | $2,575 million | up 8.8% year-over-year |
| R&DS net new bookings | $3.15 billion | up 19% year-over-year |
| R&DS contracted backlog | $34.2 billion |  |
| Last-twelve-months net new bookings | $11.3 billion | up 13% year-over-year |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Q3 revenue | third quarter of 2026 | $4,315 – $4,390 |
| Q3 Adjusted EBITDA | third quarter of 2026 | $1,000 – $1,020 |
| Q3 Adjusted diluted EPS | third quarter of 2026 | $3.19 – $3.29 |
| Full-year revenue | full-year 2026 | $17,275 million and $17,475 million |
| Full-year Adjusted EBITDA | full-year 2026 | $4,000 million and $4,050 million |
| Full-year Adjusted diluted EPS | full-year 2026 | $12.80 and $13.00 |

## Key takeaways

1. **R&D Solutions bookings hit a record level** Net new bookings were $3.15 billion, a 1.22x book-to-bill ratio, and the release calls them record-level. Strong bookings give IQVIA's clinical research business demand visibility ahead.
2. **Backlog of $34.2 billion supports future R&D revenue** About $9.2 billion of contracted backlog is expected to convert to revenue in the next twelve months, representing growth of 7.5% year-over-year. This shows how much near-term work is already contracted.
3. **AI solutions adoption is helping Commercial Solutions accelerate** Management cited increased adoption of its AI solutions as a contributor to stronger organic growth in Commercial Solutions. It positions IQVIA's AI offerings as a driver of demand, not only a branding theme.
4. **Patient solutions and engagement services grow double digits** Within Commercial Solutions, patient solutions and commercial engagement services both grew at double-digit rates, while analytics and consulting grew at a high-single-digit organic rate. Growth is broad across the segment's service lines.
5. **Acquisitions now contribute more to growth** The updated guidance assumes approximately 200 basis points of contribution from acquisitions versus 150 basis points previously. Management is leaning more on M&A alongside higher organic growth, and has raised its outlook for the year.

## Questions

**What was the biggest business development at IQVIA this quarter?** R&D Solutions posted record-level net new bookings of over $3.1 billion, a 1.22x book-to-bill ratio. Management said favorable forward-looking indicators across both segments point to sustained momentum for the rest of the year and into 2027.
**How is AI affecting IQVIA's business?** Management said increased adoption of its AI solutions contributed to a strong acceleration of organic revenue growth in Commercial Solutions. The sources give no further detail on specific AI products or usage.
**Which Commercial Solutions lines are growing fastest?** Patient solutions and commercial engagement services grew at double-digit rates. Analytics and consulting grew at a high-single-digit organic rate.
**How much future clinical research revenue is already contracted?** R&DS contracted backlog was $34.2 billion as of June 30, 2026. IQVIA expects approximately $9.2 billion of it to convert to revenue in the next twelve months, representing growth of 7.5% year-over-year.
**Did IQVIA change its outlook or how it is organized?** Yes. It raised its full-year 2026 guidance, citing stronger organic growth and a larger acquisition contribution, partly offset by a less favorable foreign exchange impact. Since January 1, 2026, it has reported two segments, Commercial Solutions and R&D Solutions, under a simplified organizational model.

## Slides and investor documents

- [Presentation](https://s201.q4cdn.com/580005511/files/doc_financials/2026/q2/IQVIA-Q2-2026-Earnings-Call-Presentation-_-vF.pdf) (Slide deck)
- [Webcast](https://events.q4inc.com/attendee/930632701) (Webcast replay)
- [Quarterly Filing](https://s201.q4cdn.com/580005511/files/doc_financials/2026/q2/IQV-2026-06-30-10Q-Filed-with-Exhibits.pdf) (Document)

